The shadow of generic challenges has repeatedly loomed around copyright’s blockbuster drug, Sildenafil, sparking questions about the prospects of related drug portfolios. While first years saw significant returns, the intellectual property lapse has opened the door for cheaper substitutes, likely reducing earnings and presenting a significant dan